TheEdgeResearch
Home / Stocks / INNMF

Amplia Therapeutics Limited (INNMF)

OTC Healthcare Biotechnology
$0.06 ▲ +7.41%
Market Cap
$29.8M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.42
52-Wk Range
0.05-0.27
CEO
Christopher J. Burns
Country
AU
Currency
USD

Amplia Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.06, up 7.41% on the session, giving a market capitalisation of $29.8M. On trailing twelve-month figures it carries a trailing P/E of -4.73, a net margin of 0.0%. Its beta of -0.42 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-4.73
Price / Sales
0.00
Price / Book
1.03
EV / EBITDA
-1.01
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.01
Current ratio
19.78
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2021-01-08
Headquarters
Melbourne, VIC, AU
About Amplia Therapeutics Limited

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Comparable companies

Amplia Therapeutics Limited is most often compared with the following Healthcare names:

ACHFFCLTEFCVALFCYYNFHBPCFOTLCPSYBFRLFTFRLFTYZIVO
More research on INNMF
INNMF technical analysis INNMF TheEdge Score Compare against peers
Open full interactive analysis & DCF →